“RATHORE EXIM”

Pharmaceutical Ingredients & Biochemical Manufacturing Plant in India - Corn-Based

Launch a pharmaceutical and biochemical manufacturing unit in India using corn-derived ingredients like dextrose, sorbitol, maltodextrin, and pharma-grade corn starch. This green, API-grade plant supports the production of natural excipients and fermentation bases essential for oral, injectable, and nutraceutical formulations. Ideal for investors seeking a sustainable, high-ROI, export-ready setup with full support for land, certification (WHO-GMP, FDA, ISO), and raw material sourcing from tribal maize mills in Chhattisgarh. Serve pharma, biotech, and medical R&D markets globally. Tap into India’s growing pharmaceutical exports with a plant aligned to global quality, low carbon footprint, and demand for clean, non-synthetic inputs.

Investment Opportunity: India

Business Overview

We are inviting foreign investors to partner in setting up a pharmaceutical and biochemical manufacturing unit using corn-derived ingredients in Chhattisgarh, India — a region rich in corn production. Corn starch, dextrose, and sorbitol are key ingredients in global pharmaceutical and biotech industries. We offer full local support and land for plant setup, with a flexible partnership model.

Why Corn-Based Ingredients?

Corn starch is a widely used excipient in tablets and capsules.
Dextrose and sorbitol are used in oral and IV formulations.
Biochemicals like lactic acid and maltodextrin are in global demand.
Suitable for pharma, nutraceuticals, medical research, and biotech industries.
Demand for non-synthetic, plant-based inputs is growing rapidly worldwide.
High-value export opportunities.
Growing global demand for natural excipients and biochemicals
India is a global pharma hub – 3rd largest exporter by volume
Corn starch is a safe, biodegradable, non-toxic base for medicines
High-margin industry with long-term demand
Opportunity to serve domestic and export markets
Used in tablets, capsules, glucose, syrups, and drug formulations

Products to Manufacture

Pharmaceutical Grade Corn Starch
Dextrose Monohydrate & Anhydrous
Sorbitol (USP Grade)
Liquid Glucose
Maltodextrin
Lactic Acid
Xylitol
Modified Starches
Biochemical fermentation base (for vaccine, probiotic industries)

Applications

Tablet binding & disintegration
Glucose IV and oral electrolyte products
Sweetening and carrier agents in syrups
Fermentation for vaccine and antibiotic manufacturing
Nutraceuticals, baby food, probiotics

Production Process

Corn starch extraction
Enzymatic hydrolysis
Fermentation (where required)
Filtration & drying
Purification and grading
Packaging (bulk or pharma packs)

Required Certifications

WHO-GMP
ISO 9001 / ISO 22000 / HACCP
FDA (India and optionally US FDA)
FSSAI (for nutrition-grade)
REACH (for EU exports)
Export registration (IEC + DGFT)

Market Scope

Pharmaceutical manufacturers in India & abroad
Export buyers in Europe, US, Japan
Biotech companies
Medical R&D labs and universities
Nutraceutical brands

Business Potential

High-profit margins
Recession-proof and export-ready industry
Scope for long-term contracts with pharma buyers
ROI possible
High-value, low-volume products = easy logistics

Why Chhattisgarh is Ideal for This Plant:

Raw material available in abundance
Tribal maize mills
land and labor cost in Kondagaon region
State support for clean-tech
Access to ports
Environmentally safe location – favorable for bio manufacturing

Our Offer to Investors

Land provided for factory setup
Photos/videos of available land
Assistance in raw material procurement from farmers
Local manpower and operational support
legal setup assistance
Full partnership model available

Investor’s Role & Benefits:

Provide investment in machinery, processing system
Technical know-how
Branding and global sales through export routes
profit margin (retail);(bulk export)
Full JV or long-term lease agreement possible

FAQs

Q1. What products will this corn-based plant manufacture?
The unit will produce pharmaceutical-grade corn starch, dextrose monohydrate & anhydrous, sorbitol (USP grade), maltodextrin, lactic acid, xylitol, liquid glucose, modified starches, and fermentation bases.

Q2. What are the main applications of these corn-derived pharmaceutical ingredients?
These ingredients are used in oral and injectable formulations, tablets, capsules, syrups, IV fluids, probiotic and vaccine fermentation, nutraceuticals, and baby food products.

Q3. Why choose corn as the raw material for pharmaceutical ingredients?
Corn is abundant, affordable, non-toxic, and biodegradable. Its derivatives like starch, dextrose, and sorbitol are widely used in the pharmaceutical and biotech industries as excipients and fermentation substrates.

Q4. What certifications are required for this type of pharma manufacturing unit?
The plant will require WHO-GMP, ISO 9001, ISO 22000, HACCP, FSSAI (for nutrition-grade), Indian FDA approval, REACH (for EU exports), and an Import Export Code (IEC).

Q5. What is the export potential for corn-based pharma ingredients?
There is high demand in Europe, the USA, Japan, and the Middle East. These ingredients are essential in pharma formulations, making this an ideal export-ready business with long-term global contracts possible.

Q6. What is the expected return on investment (ROI)?
Pharma ingredients are high-margin products. Depending on scale, expected profit margins range from 25–35% in retail and 20–30% in export. Logistics are manageable due to high-value, low-volume output.

Q7. Why is Chhattisgarh, India a suitable location for this plant?
Kondagaon in Chhattisgarh offers easy access to locally grown maize, low-cost tribal labor, available industrial land, government support for clean-tech industries, and good connectivity to export ports.

Q8. What support will the local partner provide to investors?
Support includes verified land allotment, licensing, raw material procurement, operational assistance, manpower sourcing, legal setup, and local coordination with government and suppliers.

Q9. What role is expected from the investor?
Investors are expected to bring capital, machinery, and technical know-how. They will help establish the brand, manage global sales, and ensure compliance. Full JV or lease-based models are available.

Q10. Which industries or sectors will this plant serve?
Pharmaceutical companies, biotech firms, nutraceutical brands, research labs, vaccine manufacturers, and baby food producers are key target sectors—both in India and internationally.

Q11. Is this plant aligned with ESG and sustainable manufacturing principles?
Yes, the plant uses plant-based, biodegradable materials. It supports clean-tech and low-carbon manufacturing aligned with ESG standards and eligible for green tax incentives.

Q12. What machinery and processes are involved in production?
Production includes starch extraction, enzymatic hydrolysis, fermentation (if required), drying, filtration, purification, and packaging. Machinery can be imported or sourced from Indian manufacturers.

Contact Us:

📍 Location: Kondagaon, Chhattisgarh, India